Hiutung Chu is an Assistant Professor in the Department of Pathology at UC San Diego School of Medicine. She received her BS from UC Berkeley, and her PhD in Immunology from UC Davis studying the role of antimicrobial peptides in the small intestine. For her postdoctoral training at Caltech, she studied the gut microbiome in models of inflammatory bowel disease. Her laboratory is focused on deciphering the common pathways utilized by beneficial microbes to maintain immune tolerance during health and disease.
Director, Research Proposal Development Service Office of Research Affairs
University of California, San Diego
Dr. Shannon Muir works with UCSD faculty to facilitate the development of large, interdisciplinary research proposals. She was previously a Senior Program Associate with the California Council on Science and Technology (CCST), where she staffed the Federally Funded Laboratory Affiliates program, supported fundraising efforts, and developed strategies for internal and external CCST projects. Shannon was a CCST Science Policy Fellow in 2015, serving as a consultant for the California Senate Committee on Health. During her Fellowship, she analyzed legislation related to a wide variety of topics including electronic cigarettes, internet prescribing, health insurance, and aging and long term care. Prior to the Fellowship, Shannon earned her Ph.D. in Biomedical Sciences from UC San Diego. While a graduate student, she served as the Legislative Liaison for Local & State Affairs for the UC San Diego Graduate Student Association, and as the Chair of the Graduate and Professional Student Committee on the UC Student Association Board of Directors. Shannon holds and M.S. in Pharmacology from Tulane University School of Medicine, and a B.S. in Psychobiology from UCLA.
Dr. Dahiyat has been Xencor’s president and chief executive officer since the Company’s incorporation in August 1997, and is the co-founder of Xencor, and co-inventor of Xencor’s breakthrough XmAb® technology. He has led the Company in raising over $700 million in public and private financing, creating a diverse portfolio of monoclonal antibody clinical programs for the treatment of life-threatening and debilitating diseases, and establishing alliances with leading biopharmaceutical companies that generated over $200 million in upfront payments. Dr. Dahiyat holds a Ph.D. in Chemistry from Caltech and B.S. and M.S.E. degrees in Biomedical Engineering from the Johns Hopkins University. He has co-authored numerous scientific papers in the fields of protein design and drug delivery, is an inventor of over 30 US and numerous foreign patents, and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society, and Caltech.